Cytotheryx, a Rochester firm co-founded by Mayo Clinic that uses genetically engineered pigs to make human liver cells, recently acquired the intellectual assets of a San Francisco biotech company.
Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bid to targets previously deemed undruggable.